Safe and effective paediatric formulations of the most promising antiretroviral drugs are crucial to advance the treatment and prevention of HIV in neonates, infants, children, and adolescents. The WHO Paediatric Drug Optimization for HIV (PADO-HIV) group brings together stakeholders and experts every 2–3 years to identify priority products and define research gaps in the development of new HIV drugs and formulations for children in low-income and middle-income countries. PADO-HIV 5 met from Sept 27 to Oct 15, 2021. The group evaluated HIV agents from known and novel drug classes, oral and parenteral long-acting formulations, and developments in broadly neutralising antibodies, and included focused sessions on neonates and new delivery technologies. A list of medium-term and long-term priorities was generated, and research questions were defined. This forward-looking analysis is intended to provide guidance to funders, drug developers, and researchers, and to accelerate access for children to the best HIV drugs and formulations.

最有希望的抗逆转录病毒药物的安全有效儿科制剂对于推进新生儿、婴儿、儿童和青少年 HIV 的治疗和预防至关重要。世卫组织针对艾滋病毒的儿科药物优化 (PADO-HIV) 小组每 2-3 年召集利益相关者和专家，以确定优先产品并确定为低收入和中等收入儿童开发新的艾滋病毒药物和制剂的研究差距国家。PADO-HIV 5 于 2021 年 9 月 27 日至 10 月 15 日举行会议。该小组评估了已知和新型药物类别中的 HIV 药物、口服和肠胃外长效制剂以及广泛中和抗体的发展，并包括关于新生儿和新分娩的重点会议技术。生成了一份中期和长期优先事项清单，并确定了研究问题。